Pacific Biosciences of California, Inc.
1.555
-0.32% (최근 종가 1.56)
Company profile — from Yahoo Finance
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Company information as provided by Yahoo Finance. Check the official filings before relying on it.
Market Cap
5억 달러
PER
-
Trailing 12 months
Forward P/E
-3.8배
Forward estimates
ROE
-929.3%
Return on equity
Dividend Yield
-
Beta
2.32
Volatility vs market
52주 범위에서 29% 지점입니다. 100%에 가까울수록 1년 최고가 부근입니다.
Source: Yahoo Finance
Average analyst price target
범위 $1.25 ~ $3.00 · 애널리스트 6명 · 종합의견 매수 · 출처 Yahoo Finance
Analyst rating breakdown (2026-08-01)
월가는 이 종목을 뚜렷한 매수 우위로 보고 있습니다. (매수 9 · 관망 4 · 매도 1)
Revenue trend
2억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
Net income trend
-5억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
| Year | Revenue | Operating Income | Net Income | Operating Cash Flow | Net Margin |
|---|---|---|---|---|---|
| 2025 | 2억 달러 | -6억 달러 | -5억 달러 | -1억 달러 | -341.5% |
| 2024 | 2억 달러 | -3억 달러 | -3억 달러 | -2억 달러 | -201.2% |
| 2023 | 2억 달러 | -3억 달러 | -3억 달러 | -3억 달러 | -153.0% |
| 2022 | 1억 달러 | -3억 달러 | -3억 달러 | -3억 달러 | -244.9% |
회계연도 기준 실적입니다(달력 연도와 다를 수 있습니다). 출처: Yahoo Finance. 값이 없는 항목은 채우지 않고 "-"로 둡니다.
Prices, key stats, price targets, annual financials, filings and news above come straight from Yahoo Finance · Finnhub · SEC EDGAR, so they look the same for any US-listed ticker.
Support & resistance shows above whenever my TradingView indicator is sending alerts for the ticker. No alert is set up for this one yet, so there are no levels.
Option levels · MJM Score · REAL_BUY signals come through a Google Sheet and are still limited to the fixed watchlist. We leave them out rather than guess.